SCHEMBL17093336

SCHEMBL17093336

COC(=O)[C@H]1OC2(CCCCC2)O[C@@H]1Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.41
ALDH1A1 P00352 4/20 0.40
MAPT P10636 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
ITGA4 P13612 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
CETP P11597 1/20 0.39
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38
HTR1A P08908 1/20 0.37
KDM4E B2RXH2 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
TLR9 Q9NR96 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16808502 1.00 BACE1 (0.41) BACE1ALDH1A1MAPTNPSR1ITGA4
SCHEMBL27085626 0.99 BACE1 (0.41) BACE1ALDH1A1MAPTNPSR1ITGA4
SCHEMBL27135633 0.99 BACE1 (0.41) BACE1ALDH1A1MAPTNPSR1ITGA4
SCHEMBL16795859 0.99 BACE1 (0.41) BACE1ALDH1A1MAPTNPSR1ITGA4
SCHEMBL17093301 0.99 BACE1 (0.41) BACE1ALDH1A1MAPTNPSR1ITGA4
SCHEMBL17093421 0.99 BACE1 (0.41) BACE1ALDH1A1MAPTNPSR1ITGA4
SCHEMBL16795907 0.84 TLR9 (0.40) ALDH1A1NPSR1POLBGAAMAPK1
SCHEMBL17093275 0.83 ALDH1A1 (0.37) ALDH1A1MAPTNPSR1ITGA4POLB
SCHEMBL16808421 0.83 ALDH1A1 (0.37) ALDH1A1MAPTNPSR1ITGA4POLB
SCHEMBL29418571 0.83 ALDH1A1 (0.37) ALDH1A1MAPTNPSR1ITGA4POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11896593-B2 Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-02-13 US disclosed
EP-4211125-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-19 EP disclosed
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-07-14 US disclosed
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-07-14 US disclosed
WO-2022054987-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER BIO-PHARM SOLUTIONS CO., LTD. (KR) 2022-03-17 WO disclosed
US-9937145-B2 Sulfamate derivative compound for use in preventing or treating epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2018-04-10 US disclosed
US-9937145-B2 Sulfamate derivative compound for use in preventing or treating epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2018-04-10 US disclosed
US-9834535-B2 Sulfamate derivative compounds for use in treating or alleviating pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2017-12-05 US disclosed
US-9834535-B2 Sulfamate derivative compounds for use in treating or alleviating pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2017-12-05 US disclosed
US-20160318894-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-03 US disclosed
US-20160318894-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-03 US disclosed
US-20160310461-A1 Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-10-27 US disclosed
US-20160310461-A1 Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-10-27 US disclosed
US-9221783-B2 Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-12-29 US disclosed
US-9221783-B2 Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-12-29 US disclosed
US-9221783-B2 Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-12-29 US disclosed
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-09-24 US disclosed
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-09-24 US disclosed
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318894-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain SULT2A1, STS, SULT1A1 BACE1 4301/4885ALDH1A1 920/4885MAPT 2428/4885
US-20220218702-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER SLC6A4, SLC6A3, SLC6A2 BACE1 2400/4885ALDH1A1 776/4885MAPT 573/4885
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME MYLK, MUSK, MYLK2 BACE1 3121/4885ALDH1A1 3249/4885MAPT 1413/4885
US-20160310461-A1 Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy STS, SULT2A1, GRIK5 BACE1 370/4885ALDH1A1 649/4885MAPT 827/4885
US-11896593-B2 Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder SLC6A4, SLC6A3, SLC6A2 BACE1 2400/4885ALDH1A1 776/4885MAPT 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.